SCYNEXIS Proprietary and Confidential Information The Discovery and Clinical Evaluation of the Cyclophilin Inhibitor SCY-635 in HCV Infected Subjects Michael.
Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated Interferon alpha-2a in treatment naïve chronic.
Challenges in Managing Hepatitis C Virus Infection
Future HCV Treatment Paradigms Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and Gastroenterology
